Drug Research
Samsung Bioepis and C-Bridge Capital to Develop and Commercialize Next-Generation Biosimilars in China
Samsung Bioepis Co., Ltd. announced its expansion in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference LUCENTIS®...
Drug Research
Pathios Therapeutics and Sygnature Discovery sign strategic partnership
Pathios Therapeutics, an innovative biotech company focused on the development of first-in-class therapies for autoimmune diseases and immuno-oncology and Sygnature Discovery have announced a strategic partnership to accelerate Pathios’ drug discovery and development programmes. As part...
Drug Research
Pharm-Olam Enrolls Patients in Zealand Pharma Orphan Drug Study
Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for rare and orphan diseases along with oncology, infectious diseases, and vaccines, is now enrolling patients in the U.S. and Europe into a pivotal Phase III study within the...
Drug Research
IDDI starts Collaborative Research on Ground-Breaking Statistical Method for individualization of Therapy
The treatment of patients in clinical practice relies on the results of randomized clinical trials. The statistical methods currently used to test the treatment effects in such trials take into account a single criterion called "primary endpoint". ...
Drug Research
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies
Kyn Therapeutics, a clinical-stage biotechnology company advancing research into new immunometabolic therapies for treating cancer, announced it has entered into a global strategic collaboration with Celgene Corporation. The goal of the collaboration is to develop novel...
Drug Research
Branched-Chain Amino Acids Found to Regulate the Development and Progression of Cancer
Researchers at A*STAR's Singapore Bioimaging Consortium (SBIC) have discovered that branched-chain amino acids (BCAAs) in tumours can be targeted to prevent and treat cancer. Together with collaborators from the United States and National Cancer Centre Singapore...
Drug Research
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Regeneron Pharmaceuticals, Inc. and Sanofi have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 Agreement was scheduled to end in approximately mid-2020, and this revision provides for ongoing collaborative...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read